Pro-fibrogenic role of alarmin high mobility group box 1 in HIV-hepatitis B virus coinfection.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
18
11
2022
medline:
27
1
2023
entrez:
17
11
2022
Statut:
ppublish
Résumé
Liver disease is accelerated in people with HIV (PWH) with hepatitis B virus (HBV) coinfection. We hypothesized that liver fibrosis in HIV-HBV is triggered by increased hepatocyte apoptosis, microbial translocation and/or HIV/HBV viral products. Sera from PWH with HBV coinfection versus from those with HBV only or putative mediators were used to examine the pathogenesis of liver disease in HIV-HBV. We applied sera from PWH and HBV coinfection versus HBV alone, or putative mediators (including HMGB1), to primary human hepatic stellate cells (hHSC) and examined pro-fibrogenic changes at the single cell level using flow cytometry. High mobility group box 1 (HMGB1) levels in the applied sera were assessed according to donor fibrosis stage. Quantitative flow cytometric assessment of pro-fibrogenic and inflammatory changes at the single cell level revealed an enhanced capacity for sera from PWH with HBV coinfection to activate hHSC. This effect was recapitulated by lipopolysaccharide, HIV-gp120, hepatocyte conditioned-media and the alarmin HMGB1. Induction of hepatocyte cell death increased their pro-fibrogenic potential, an effect blocked by HMGB1 antagonist glycyrrhizic acid. Consistent with a role for this alarmin, HMGB1 levels were elevated in sera from PWH and hepatitis B coinfection compared to HBV alone and higher in those with HIV-HBV with liver fibrosis compared to those without. Sera from PWH and HBV coinfection have an enhanced capacity to activate primary hHSC. We identified an increase in circulating HMGB1 which, in addition to HIV-gp120 and translocated microbial products, drove pro-fibrogenic changes in hHSC, as mechanisms contributing to accelerated liver disease in HIV-HBV.
Identifiants
pubmed: 36384811
doi: 10.1097/QAD.0000000000003435
pii: 00002030-202303010-00004
doi:
Substances chimiques
Alarmins
0
HMGB1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-411Subventions
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901374
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment . AIDS 2017; 31:2035–2052.
Tsai WC, Hsu WT, Liu WD, Sun HY, Chuang YC, Huang YS, et al. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection . Liver Int 2019; 39:1408–1417.
van Welzen BJ, Smit C, Boyd A, Lieveld FI, Mudrikova T, Reiss P, et al. Decreased all-cause and liver-related mortality risk in HIV/hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral Therapy . Open Forum Infect Dis 2020; 7:ofaa226.
Kouame GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, et al. Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high hbv replication . Clin Infect Dis 2018; 66:112–120.
Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, et al. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B . Liver Int 2021; 41:2874–2884.
Sterling RK, King WC, Khalili M, Chung RT, Sulkowski M, Jain MK, et al. A prospective study evaluating changes in histology, clinical and virologic outcomes in HBV-HIV co-infected adults in North America . Hepatology 2021; 74:1174–1189.
Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology . Nat Commun 2013; 4:2823.
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression . Nat Rev Gastroenterol Hepatol 2021; 18:151–166.
Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation . Nat Rev Gastroenterol Hepatol 2017; 14:397–411.
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection . Nat Med 2006; 12:1365–1371.
Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities . Nat Rev Microbiol 2012; 10:655–666.
Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis . Nat Med 2007; 13:1324–1332.
Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells . Hepatology 2003; 37:1043–1055.
Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis . Gastroenterol Res Pract 2010; 2010:1925438 pages.
Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection . Gastroenterology 2011; 141:1220–1230. e1221-1223.
Getachew A, Abbas N, You K, Yang Z, Hussain M, Huang X, et al. SAA1/TLR2 axis directs chemotactic migration of hepatic stellate cells responding to injury . iScience 2021; 24:102483.
Medrano LM, Garcia-Broncano P, Berenguer J, Gonzalez-Garcia J, Jimenez-Sousa MA, Guardiola JM, et al. Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients . AIDS 2018; 32:1095–1105.
Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, et al. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of didanosine . AIDS 2016; 30:1771–1780.
Marquez M, Romero-Cores P, Montes-Oca M, Martin-Aspas A, Soto-Cardenas MJ, Guerrero F, et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection . PLoS One 2015; 10:e0119568.
Sacchi P, Cima S, Corbella M, Comolli G, Chiesa A, Baldanti F, et al. Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection . Dig Liver Dis 2015; 47:218–225.
Singh K, Zerbato J, Zhao W, Baat S, Deleage C, Tennakoon S, et al. Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection . PLoS Pathogens 2020; 16:e1008744.
Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, Ho DD. Identification and quantitation of HIV-1 in the liver of patients with AIDS . AIDS 1992; 6:65–70.
Iser DM, Warner N, Revill PA, Solomon A, Wightman F, Saleh S, et al. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen . J Virol 2010; 84:5860–5867.
Hufert FT, Schmitz J, Schreiber M, Schmitz H, Racz P, von Laer DD. Human Kupffer cells infected with HIV-1 in vivo . J Acquir Immune Defic Syndr 1993; 6:772–777.
Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis . Hepatology 2010; 52:612–622.
Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy . J Infect Dis 2009; 199:974–981.
Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis . Gut 2010; 59:513–520.
Salloum S, Holmes JA, Jindal R, Bale SS, Brisac C, Alatrakchi N, et al. Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types . Hepatology 2016; 64:1951–1968.
Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV, et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression . AIDS 2011; 25:197–205.
Macias J, Japón MA, Sáez C, Palacios RB, Mira JA, García-García JA, et al. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection . J Infect Dis 2005; 192:1566–1576.
Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA. HIV induces TRAIL sensitivity in hepatocytes . PLoS One 2009; 4:e4623.
Vlahakis SR, Villasis-Keever A, Gomez Timothy S, Bren, Gary D, Paya Carlos V. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4 . J Infect Dis 2003; 188:6.
Bedossa P, Poynard T, group M. An algorithm for the grading of activity in chronic hepatitis . Hepatology 1996; 24:289–293.
Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis M, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) . Eur J Immunol 2021; 51:2708–3145.
Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication . Antimicrob Agents Chemother 1997; 41:1715–1720.
Tacke F, Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques . Expert Rev Gastroenterol Hepatol 2012; 6:67–80.
Gaskell H, Ge X, Nieto N. High-mobility group box-1 and liver disease . Hepatol Commun 2018; 2:1005–1020.
Ge X, Arriazu E, Magdaleno F, Antoine DJ, Dela Cruz R, Theise N, et al. High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycation end products in mice . Hepatology 2018; 68:2380–2404.
Arriazu E, Ge X, Leung TM, Magdaleno F, Lopategi A, Lu Y, et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury . Gut 2017; 66:1123–1137.
Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway . World J Gastroenterol 2012; 18:679–684.
Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities . Chem Biol 2007; 14:431–441.
Girard JP. A direct inhibitor of HMGB1 cytokine . Chem Biol 2007; 14:345–347.
Albayrak A, Uyanik MH, Cerrah S, Altas S, Dursun H, Demir M, et al. Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? . Viral Immunol 2010; 23:633–638.
Del Corno M, Cappon A, Donninelli G, Varano B, Marra F, Gessani S. HIV-1 gp120 signaling through TLR4 modulates innate immune activation in human macrophages and the biology of hepatic stellate cells . J Leukoc Biol 2016; 100:599–606.
Hong F, Saiman Y, Si C, Mosoian A, Bansal MB. X4 Human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4 . PLoS One 2012; 7:e33659.
Yang H, Wang H, Chavan SS, Andersson U. High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule . Mol Med 2015; 21: (Suppl 1): S6–S12.
Shi X, Yu L, Zhang Y, Liu Z, Zhang H, Liu P, et al. Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway . Int Immunopharmacol 2020; 84:106578.
Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors . Am J Physiol Cell Physiol 2006; 290:C917–C924.
Zhang Z, Lin C, Peng L, Ouyang Y, Cao Y, Wang J, et al. High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells . Life Sci 2012; 91:207–212.
He Q, Fu Y, Ding X, Li D, Wang Z, Tian D, et al. Correction: high-mobility group box 1 induces endoplasmic reticulum stress and activates hepatic stellate cells . Lab Invest 2019; 99:439–442.
Ni YA, Chen H, Nie H, Zheng B, Gong Q. HMGB1: an overview of its roles in the pathogenesis of liver disease . J Leukoc Biol 2021; 110:987–998.
Vannier AGL, Wardwell B, Fomin V, PeBenito A, Wolczynski N, Piaker S, et al. Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder . Alcohol 2021; 95:37–43.
Zhong H, Gui X, Hou L, Lv R, Jin Y. From inflammation to fibrosis: novel insights into the roles of high mobility group protein box 1 in schistosome-induced liver damage . Pathogens 2022; 11:289.
Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection . AIDS 2007; 21:869–871.
Li J, Wang FP, She WM, Yang CQ, Li L, Tu CT, et al. Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B . J Viral Hepatitis 2014; 21:129–140.
Inkaya AC, Demir NA, Kolgelier S, Sumer S, Demir LS, Ural O, et al. Is serum high-mobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B? . Medicine (Baltimore) 2017; 96:e7547.
Wang LW, Chen H, Gong ZJ. High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B . Hepatobiliary Pancreat Dis Int 2010; 9:499–507.
Sitia G, Iannacone M, Müller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice . J Leukoc Biol 2007; 81:100–107.
Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4 . J Infect Dis 2003; 188:1455–1460.
Balasubramanian A, Ganju RK, Groopman JE. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes . J Biol Chem 2003; 278:35755–35766.
Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, Hirschel B, et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen . J Exp Med 1998; 187:1295–1303.
Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susarla S, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms . J Leukoc Biol 2004; 76:994–1001.
Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis . Immunity 2018; 49:740–753. e747.
Leite CDS, Bonafe GA, Carvalho Santos J, Martinez CAR, Ortega MM, Ribeiro ML. The anti-inflammatory properties of licorice (glycyrrhiza glabra)-derived compounds in intestinal disorders . Int J Mol Sci 2022; 23:4121.